European Society for Medical Oncology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Overall survival (OS) results from the Phase III MONALEESA-2 (ML)-2 trial of postmenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)

Gabriel N. Hortobagyi

  • Presentation # LBA17_PR
    Sept 19, 2021 | 2:10 PM CEST

This presentation will be available once the congress embargo lifts

Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

Peter A. Fasching

  • Presentation # 233P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)

Yoon Sim Yap

  • Presentation # 232P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

Efficacy and safety of ribociclib (RIB) in combination with letrozole (LET) in patients with estrogen receptor–positive advanced breast cancer (ABC): Secondary and exploratory results of phase 3b RIBECCA study

Thomas Decker

  • Presentation # 247P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Luca Malorni

  • Presentation # 292P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study

Susan Dent

  • Presentation # 324P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

Antineoplastic (ANP) Therapies (Tx) After Alpelisib (ALP) or Placebo (PBO) + Fulvestrant (FUL) in Patients (Pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2–), PIK3CA-Mutated (Mut) Advanced Breast Cancer (ABC): An Analysis From SOLAR-1

Fabrice André

  • Presentation # 309P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer

Zhimin Shao

  • Presentation # 238P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts

A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc)

Lisa A. Carey

  • Presentation # 275P – Poster
    Sept 16, 2021 | 8:30 AM CEST

This presentation will be available once the congress embargo lifts
View list of select presentations for this compound